The opening paper of a symposium on cancer to facing surgeons. In some ways the verbal battles your society is a daunting prospect. To dwell as that rage round these controversial issues are asked, on the nature of cancer, and its biochemical comparable to those at the turn of the century when aspects in particular, without the vision of Warburg the pioneer immunologists sought cures for infections or the experience of Bodansky (l975) is inviting scorn. prior to the discovery and exploitation of the I have chosen to take a more pragmatic view of antibiotics. Despite the great advances in cancer considering how we stand today in clinical cancer therapy we are using only half-way technology, to management and to try to identify some areas that use Lewis Thomas's expression, whose writings will may soon be making fresh demands on your labora-be well known to readers of the New England tory resources.
Journal of Medicine. In no way can the current The United States Government having backed a modalities of therapy by likened to the specific winner in the race to the moon has turned to another conquest of poliomyelitis by vaccination, in which area which reflects the desires of the people and the biological knowledge and technology were provides a challenge to American resources of harnessed together effectively. intellect and technology. The conquest of cancer is A dissatisfaction with the end results of therapy the chosen goal, the National Cancer Plan its of many common cancers is widely felt among all strategy, with a budget of 800 million dollars this those who are closely connected with this branch of year and still rising, as the sign of their good faith. medicine in Britain. Although, when compared with Predictably the injection of so much money into the optimists in the United States we appear to have cancer research has incurred phrenetic activity, a better appreciation that man was not born to be producing a plethora of work ranging from that of immortal, an increased risk of cancer with age is a the highest quality to the pedestrian and distinctly well established biological phenomenon. Epidemicdubious. In Europe interest in the cancer problem is logists claim that much of its incidence is the growing and undoubtedly strengthened as we watch outcome of our own folly and the price for the what is happening in the United States. Medical convenience of our mode of life. This may be so, practitioners and biomedical scientists are now but it is equally sure that in the next few years the under continuous bombardment by a deluge of pattern is unlikely to undergo dramatic change. publications that grow each year, like cancer itself, Certainly modern medicine can do a great deal to and may well eventually stifle any desire to try to palliate the once feared consequences of advanced make a balanced judgment on what is the right malignant disease, and indeed may often preserve course of action. The various options open at each life in the elderly, so that they may later die of decision point are defended vehemently by their another cause. However, it is cancer in physically protagonists, some emulating the politicians in the active people, whatever their age, that taxes the persuasiveness of their arguments and are attacking clinicians' skill, for the goal is surely not palliation. cancer with the blind faith of the crusaders taking The control and elimination of tumour cells that it out of all proportion to the illnesses that beset cannot be excised or are not radiosensitive is the man as a whole.
central issue that decides the ultimate success or The media of mass communication pick up, failure of therapy. In about a quarter of cancers amplify and distort the messages, so that what a few eventual failure can be predicted at the outset, for years ago would have barely raised a murmur of the metastases are already visible, though the interest amongst a few specialists, is now rapidly duration of life may vary from weeks to several brought before the public through the pages of years. However, for the remainder success is a Newsweek or Readers' Digest. This creates pressures probability function with the odds shortening on the profession, and owing to the emotive nature according to many well proved associations between of cancer it may lead to taking hasty decisions which, tumour type, grade, and stage. The patient with the because of the slow natural time course of cancer, best prognosis may have micrometastases that may could take several years to know whether they were lie dormant for several years; conversely a few wise or imprudent. The arguments for and against with the worst prognosis will be cured by surgery. the use of prophylactic adjuvant chemotherapy in
The clinical biochemist has an important role to breast cancer is typical of the current dilemma play in the design of new strategies for the improve-ment in the end results of cancer management. Already there is a growing awareness of the way in which tumours, through the production of hormones or other pharmacologically active molecules, can produce complex syndromes whose nature will only be revealed by laboratory tests. Bondy (1976) more advanced level the biochemical disorders that follow the mechanical obstruction of the major systems, such as the gut, bile ducts, and ureters, are all well known and are part of the usual daily work load. However, with some of these groups of diseases associated with cancer, at least at their onset, adequate clinical information is vital if the subtle changes are to be identified and the correct sequence of tests set up to identify the true cause of the lesion and intervention made as soon as possible. This is all part of the general alertness that is required, and success or failure will often depend on the rapport between the laboratory and the clinician with each fully understanding the other's requirements.
I have indicated it is the disseminated aspect of the disease that is the real challenge. Unfortunately, we have only a few tumours in which the combined modalities of surgery, radiotherapy, and chemotherapy cure tumours that have disseminated. If we exclude the leukaemias and lymphomas, then at least half the patients with the following solid tumours will have a normal life expectancy, provided they are treated adequately: Wilms's tumour, choriocarcinoma, Ewing's sarcoma, retinoblastoma, and rhabdomyosarcoma (Zubrod, 1975) . This advance, in albeit a set of rare tumours, is sufficiently encouraging to warrant sustained effort to try to find ways of treating the common disseminated tumours arising from the bronchus, gastrointestinal tract, and genitourinary organs. There are 44 active cancer chemotherapy compounds available, grvmg an almost infinite opportunity for multiple drug regimens, ringing the changes in their combination, dose, and timing. For obvious reasons the systems are tested in advanced tumours in which it is possible to obtain objective evidence of response as defined by a 50 % reduction of the tumour mass, estimated clinicallya very crude measurement compared to laboratory studies. However, with the possible exceptions of HCG in choriocarcinoma, lysozyme in myelomonocytic leukaemia, and monoclonal gamma globulins in myelomatosis, there are no chemical indicators that strictly correlate with tumour mass.
There is much evidence to support the view that it is advantageous to the patient to have the minimum delay between suspicion and confirmation and treatment of symptomatic cancer, though attitudes are far more ambivalent as to the wisdom of allocating large resources for population screening except in the more accessible tumours such as cervix.
We are now moving into an interesting time, for not only is the laboratory called to aid in establishing the diagnosis of cancer but it will soon be called upon to extend its monitoring services. The physicians now require systems to enable them to watch the progress of cancer that cannot be detected by conventional clinical and radiological techniques. These arise in two main situations, (a) minimal residual disease complicating a primary tumour in which it was known tumour was left behind but cannot be detected clinically once the wound is closed, (b) the monitoring of patients after apparently successful treatment to distinguish as easily as possible those in whom the probability of recurrence has been translated into established fact. It is hoped that by such a process the institution of appropriate therapy may have a better chance of being effective than waiting for the tumour to grow to a size to cause symptoms. Should treatment be instituted, then the clinician will require laboratory based information on how the cancer is responding. The biochemical detection of cancer has recently been reviewed (Munro Neville and Cooper, 1975) . It was also the topic of a symposium in the United States (Cancer, 1976) . Readers are referred to the references for details. Here I wish to consider the general tactics of the use of these markers as they affect the clinical biochemist. There would seem much in favour of trying to assemble an array of tests that are particularly suitable for individual cancers. The various oncofetal antigen assays alone seem to be insufficient to tell with certainty that a tumour is present, its· probable site, and reaction to therapy. However, taking the experience of studies of benign hepatic disease, there is now considerable experience of building up and testing the use of assays of non-specific tests that collectively provide a basis for the discrimination of the various forms of disease (Solberg, 1975) .
The assay needs: (a) elements that alert attention to the probability of cancer being present; (b) elements that draw attention to the most likely organ systems involved; (c) measurements that relate to tumour mass and its response to therapy. In general terms the first of these requirements will be fulfilled by a combination of oncofetal antigens and nonspecific reactions to cancer. In the later class comes the alternation of the profile of acute reactant proteins and the increase of certain enzymes notably, lactate dehydrogenase, glucose-6-phosphate isomerase (Schwartz, 1976) and alteration of the isozymes, though the latter is more often a feature of tumour tissue and its adjacent "normal" tissue than in the blood.
To draw attention to the site, the classical areas are the liver and the bone. Elevation of serum gamma glutamyl transferase (rGT) is a very sensitive indicator of metastases in the liver, but caution should be taken in its interpretation as it is affected by drugs and alcohol, and perhaps it is wise to delay any necessity for intervention until the suspicion is confirmed by a rising 5' nucleotidase and alkaline phosphatase. Suspicion of bone metastases can be aroused from an elevation in the levels of the phosphatases in the sera, but the osteolytic lesions of breast cancer may cause less disturbance than the osteoblastic reaction to prostatic cancer. Studies of hydroxyproline secretion, can also be made, but this more demanding test might be reserved for selected groups, such as women with a high risk of metastatic breast cancer.
The use of non-specific tests is illustrated by our studies of the acute phase reactant proteins (APRP) (Cooper et al., 1976 a, b) . It is well known that the proteins listed in Table 2 can be disturbed in (Bacchus, 1975) , but equally they tend to alter in response to wounding, various acute chronic inflammatory processes, and connective tissue diseases. This led 10 years ago to their being discarded as aids to diagnosis. However, since
The nature of cancer 469 then there have been advances in immunological techniques that enable several APRPs to be measured in the same specimen. Furthermore, the variation for each protein in health for a given individual is relatively small, ± 20% of the mean for haptoglobin . Hence, although the normal limits for a population may be wide, repeated observation on an individual can detect change within the normal range that are associated with recurrence of cancer or response to therapy. Secondly, although the APRPs can respond to many signals, the patterns of their response tend to be different in various diseases. Hence the non-specificity of the individual test can be compensated by considering the profile of several APRPs and especially watching changes in this pattern with time. In this manner a cascade of reactions can be found in which there is recruitment with time of various components. For example, in colo-rectal cancer, breast cancer, and bladder cancers an elevated haptoglobin is the most sensitive indicator, followed by rising acid glycoprotein and antitrypsin and chymotrypsin, while a falling prealbumin, a negative reactant, is a sign of an inability of the body to support the cancer load and tends to be the prelude to many biochemical disturbances that are associated with advanced cancer. The correlation of the APRP and CEA varies considerably and in practice is found to respond to factors that are often independent of the CEA production and degradation rates. The correlation coefficients with CEA in colo-rectal cancer are respectively: haptoglobin, r = 0.26, antitrypsin, r = 0.53, acid glycoprotein, r = 0.403 and prealbumin, r = -0.407.
An array consisting of CEA, ')'GT, 5' nucleotidase, and the four APRPs has been found to be useful to monitor the effects of chemotherapy in large bowel cancer. In approximately two-thirds of the patients their changes closely mirrored the clinical course as reassessed every six weeks; in one-third information from the tests gave advanced warning that the therapy had failed to halt the progress of the cancer. The APRP was the first of the indicators to show change in 10/43 incidents of improvement or failure to respond to chemotherapy.
In a similar fashion there is evidence that the profile of the APRPs changes in bladder cancer, and this cannot be explained as the result of coincidental infection. In both bladder and breast cancer, elevations of haptoglobin are usually the most sensitive response, but in breast cancer and prostate cancer care is needed in interpreting the profile in view of the effects of oestrogens on the synthesis of APRPs.
Apart from assessing their value as indicators the physiological effects of alterations of the APRPs with antiproteolytic actions is still unknown, yet up to a four-fold increase in the serum antitrypsin has been encountered on several occasions in our series. However,like many other changes such as alterations of lymphocyte or macrophage activity, the beneficial effects may be swamped by the tumour mass.
As yet there is insufficient information on whether particular configurations of the protein profile are associated with the fast or slow growing tumours. Obviously a prediction of the natural evolution of the tumour would be most valuable, as it is probable that the slow growing group will be more resistant to chemotherapy and may not cause symptoms for many months after their detection by a monitoring system.
Just as monitoring has been shown to be feasible and can provide the physician with evidence of tumour recurrence when it is asymptomatic, it may well contribute to the assessment of the prognosis. The preoperative levels of CEA have a prognostic significance in bowel cancer, the high levels being associated with increased risk of recurrence. A combination of the operative findings and preoperative biochemical tests may define the optimal frequency for follow-up studies, and a plan could be envisaged in which laboratory monitoring was intercalated with routine physical examination in high-risk groups.
The success of such an approach needs the selection of the optimum array of tests and a method of comparing all the antecedent measurements to the current test. It is this aspect of the logistics of the exercise that may be difficult to organise, though in major cancer centres with adequate computer support it is well within the compass of current technology. The next question that will soon be pressing for an answer is, Will the benefit to the patients warrant the additional expense? Only time and experience will tell. Maybe for the meanwhile we should proceed with caution, by linking groups of hospitals and laboratories to make trials under controlled conditions, yet on a sufficient scale to appreciate how to find the subsets that make up a population bearing a particular cancer. This is a typical minor advance offered by using half-way technology, but until the tumour immunologists come up with specific and stoichiometric indicators of cancer it would seem one way to provide a better service to the oncologist. However, speaking as a laboratory scientist, no matter how sure we are of the interpretation of the measurements made in the laboratory, I do not envy the oncologist's task of deciding whether intervention is required in the asymptomatic patient with metastatic adenocarcinoma. But then that is their world and responsibility, just as the laboratory is ours. 
